Literature DB >> 9552991

Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue.

P Bruzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9552991      PMCID： PMC1112979          DOI： 10.1136/bmj.316.7139.1181

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Authors:  B Fisher; J Dignam; J Bryant; A DeCillis; D L Wickerham; N Wolmark; J Costantino; C Redmond; E R Fisher; D M Bowman; L Deschênes; N V Dimitrov; R G Margolese; A Robidoux; H Shibata; J Terz; A H Paterson; M I Feldman; W Farrar; J Evans; H L Lickley
Journal:  J Natl Cancer Inst       Date:  1996-11-06       Impact factor: 13.506

2.  Breast cancer trial stopped early.

Authors:  D Josefson
Journal:  BMJ       Date:  1998-04-18

3.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.

Authors:  S E Karp; P N Tonin; L R Bégin; J J Martinez; J C Zhang; M N Pollak; W D Foulkes
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

Review 4.  Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial.

Authors:  T L Bush; K J Helzlsouer
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

Review 5.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321
  5 in total
  5 in total

Review 1.  Tamoxifen and breast cancer prevention: what should you tell your patients?

Authors:  V Goel
Journal:  CMAJ       Date:  1998-06-16       Impact factor: 8.262

Review 2.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 4.  Breast cancer prevention trials.

Authors:  D J Rhodes; L C Hartmann; E A Perez
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

5.  First do no harm: extending the debate on the provision of preventive tamoxifen.

Authors:  B P Will; K M Nobrega; J M Berthelot; W Flanagan; M C Wolfson; D M Logan; W K Evans
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.